-
RVMD Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Revolution Medicines (RVMD)
Company Profile
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 204.15 mm | 204.15 mm | 204.15 mm | 204.15 mm | 204.15 mm | 204.15 mm |
Cash burn (monthly) | 24.86 mm | 13.05 mm | 58.57 mm | 54.43 mm | 43.47 mm | 44.98 mm |
Cash used (since last report) | 100.01 mm | 52.50 mm | 235.58 mm | 218.94 mm | 174.86 mm | 180.90 mm |
Cash remaining | 104.14 mm | 151.65 mm | -31.43 mm | -14.79 mm | 29.29 mm | 23.25 mm |
Runway (months of cash) | 4.2 | 11.6 | -0.5 | -0.3 | 0.7 | 0.5 |
13F holders | Current |
---|---|
Total holders | 258 |
Opened positions | 56 |
Closed positions | 37 |
Increased positions | 87 |
Reduced positions | 67 |
13F shares | Current |
---|---|
Total value | 7.30 tn |
Total shares | 191.37 mm |
Total puts | 620.00 k |
Total calls | 260.10 k |
Total put/call ratio | 2.4 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 14.91 mm | $676.23 bn |
BlackRock | 13.87 mm | $628.86 bn |
Wellington Management | 11.40 mm | $517.05 bn |
Farallon Capital Management | 11.32 mm | $513.26 bn |
Baker Bros. Advisors | 7.57 mm | $343.26 bn |
Farallon Capital Partners | 6.47 mm | $0.00 |
Nextech Invest | 6.30 mm | $285.56 bn |
JHG Janus Henderson | 6.14 mm | $278.28 bn |
Biotechnology Value Fund L P | 5.98 mm | $0.00 |
FMR | 5.88 mm | $266.47 bn |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
21 Jan 25 | Jeff Cislini | Common Stock | Sell | Dispose S | No | Yes | 40.5 | 2,406 | 97.44 k | 39,222 |
18 Dec 24 | Goldsmith Mark A | Common Stock | Option exercise | Acquire M | No | No | 0.49 | 30,846 | 15.11 k | 355,902 |
18 Dec 24 | Goldsmith Mark A | Stock Option Common Stock | Option exercise | Dispose M | No | No | 0.49 | 30,846 | 15.11 k | 0 |
16 Dec 24 | Jack Anders | Common Stock | Sell | Dispose S | No | Yes | 45.4038 | 2,635 | 119.64 k | 96,470 |
16 Dec 24 | Jeff Cislini | Common Stock | Sell | Dispose S | No | Yes | 45.4038 | 1,599 | 72.60 k | 41,628 |
16 Dec 24 | Stephen Michael Kelsey | Common Stock | Sell | Dispose S | No | Yes | 45.4038 | 4,663 | 211.72 k | 259,745 |